Sanofi's Genzyme unit paid Alnylam approximately $700M for a 12% equity stake plus expanded ex-U.S. rights to Alnylam's RNAi rare-disease pipeline including patisiran. The deal anchored Sanofi's bet on RNAi as a platform and was one of the largest equity-plus-rights packages of 2014.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Neutral
Pipeline outcome
Assets Advanced
Assessment window: 10yr post-close.
Key facts
AnnouncedJan 13, 2014
ClosedFeb 04, 2014
Deal value$700M
Deal typeLicensing/Option
Therapeutic areaATTR amyloidosis and other rare genetic diseases
IndicationsATTR amyloidosis and other rare genetic diseases